Review of Targeted Therapy for HER-2 Positive Breast Cancer

Abstract

In this paper, by searching the relevant literature on the study of dual targeting therapy for HER-2 positive breast cancer in recent years, we summarized and analyzed the long-term follow-up results and new research on neoadjuvant, adjuvant and late rescue therapy of HER-2 positive breast cancer with anti-HER-2 dual targeting regimen, so as to further improve the clinical understanding of anti-HER-2 dual targeting therapy. Many research results show that anti-HER-2 double targeted therapy can achieve higher pathological complete remission rate and better prognosis in neoadjuvant therapy for HER-2 positive breast cancer, and also can obtain better survival benefit in adjuvant therapy and late rescue therapy. However, more large-scale prospective clinical studies and time validation are still needed to find the best targeted drug combination with more benefits, fewer complications and more economy.